Sanofi Change in Assets/Liabilities 2010-2025 | SNY
Sanofi annual/quarterly change in assets/liabilities history and growth rate from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- Sanofi change in assets/liabilities for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Sanofi change in assets/liabilities for the twelve months ending March 31, 2025 was $-2.966B, a 388.12% decline year-over-year.
- Sanofi annual change in assets/liabilities for 2024 was $-0.973B, a 156.21% decline from 2023.
- Sanofi annual change in assets/liabilities for 2023 was $1.731B, a 99.1% increase from 2022.
- Sanofi annual change in assets/liabilities for 2022 was $0.869B, a 31.53% decline from 2021.
Sanofi Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-973 |
| 2023 |
$1,731 |
| 2022 |
$869 |
| 2021 |
$1,269 |
| 2020 |
$-451 |
| 2019 |
$472 |
| 2018 |
$-961 |
| 2017 |
$277 |
| 2016 |
$593 |
| 2015 |
$1,969 |
| 2014 |
$682 |
| 2013 |
$267 |
| 2012 |
$-414 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
